Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04825834 · ClinicalTrials.gov registry record
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
A clinical trial, sponsored by Delfi Diagnostics.
- Completed
- Registry status
- 2,992
- Enrollment target
NCT04825834: Completed study, sponsored by Delfi Diagnostics.
NCT04825834 is a clinical trial that has completed, run by Delfi Diagnostics. The registered enrollment target is 2,992 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04825834 has completed, sponsored by Delfi Diagnostics.
- COMPLETED
- Registry status
- 2,992 participants
- Enrollment target
Study Summary
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,992 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2025-07-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04825834
The ClinicalTrials.gov registry entry for NCT04825834 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,992 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delfi Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT04825834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04825834 about?
NCT04825834 is a clinical study titled "DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)". The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
What is the current status of trial NCT04825834?
This trial is currently completed. The enrollment target is 2,992 participants. The study started on 2021-03-22. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT04825834?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT04825834?
This trial is sponsored by Delfi Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.